Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for Nuclear Factor I B (compound)
Most Correlated Studies
- Lung of Nuclear factor I B conditional knockout mice at E18.5
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
Most Relevant Literature
- Nuclear factor I/B: Duality in action in cancer pathophysiology.
- microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4…
- Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenviron…
- Gene expression profile of human colorectal cancer identified NKTR as a biomarker for liver metastas…
- Combined allelic dosage of Nfia and Nfib regulates cortical development.
Most Relevant Clinical Trials
- Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
- NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand …
- R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
- Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the H…
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix…
